Medicaid To Seek Repayment Of Rebates On Drugs Sold To HMO Repackagers
Executive Summary
The Health Care Financing Administration intends to follow an HHS Inspector General recommendation to require drug manufacturers who excluded sales to HMO repackagers from their Medicaid best price determinations to pay back the lost rebates.
You may also be interested in...
Pfizer Pricing Data Subpoenaed By GAO As Part Of Medicaid Investigation
Pfizer has until Jan. 14 to respond to the General Accounting Office's request for documents related to price reporting practices under the Medicaid drug rebate program
Pfizer Pricing Data Subpoenaed By GAO As Part Of Medicaid Investigation
Pfizer has until Jan. 14 to respond to the General Accounting Office's request for documents related to price reporting practices under the Medicaid drug rebate program
Medicaid Pharmacy Reimbursement Should Reflect Actual Cost - HHS IG
Medicaid reimbursement to pharmacies should be adjusted to reflect the actual acquisition cost for brand name drugs, estimated at 21.84% below average wholesale price, a HHS Inspector General report states.